News

Applications are open for the MedTech Innovator Competition 2021 »

MedTech Innovator is the largest accelerator of medical devices in the world. We provide an unparalleled platform to support startups with the access, visibility, and network to bring their innovations to patients. Our alumni have raised over $2B in follow-on funding, brought 75 products to the market, and achieved 11 acquisitions. In its latest CipherBio report, Silicon Valley Bank recognized MTI as having the most active fundraising portfolio in 2020 of any accelerator.

Applications are open for the 2021 program. This is a highly selective and unique opportunity for startups and scale-ups to be showcased and gain access to healthcare stakeholders including investors, customers, and industry leaders such as Johnson & Johnson, Baxter, Olympus, W. L. Gore, Nipro, Edwards Lifesciences, Dexcom, Asahi Intecc, Fujikura, Jabil Healthcare, Maxim Integrated Products, and others. This year, up to $500,000 in non-dilutive prizes will be awarded.

Showcase at Leading Industry Conferences

Among other benefits, companies selected for the 2021 program will receive showcase presentation slots and one complimentary registration to the MedTech Innovator Summit and WSGR Medical Device Conference in June as well as The MedTech Conference powered by AdvaMed in September.

Prizes

Compete for up to $500,000 in non-dilutive cash prizes and in-kind awards

Who Should Apply?

All early to mid-stage medical device, diagnostic, or digital health companies are encouraged to apply. Preference for the Accelerator program will be given to companies that have not yet raised a Series B. All companies are eligible for the Showcase program.

Companies do not need to relocate to participate. MedTech Innovator does not charge or take equity for participation, and there is no application fee.

Apply Now

Recent News

09/16/2025

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The new site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly’s emerging bioconjugate platform and monoclonal antibody portfolio. Earlier

09/09/2025

ATCC Receives Contract to Advance Industrial Biomanufacturing and Produce Synthetic Aviation Fuel Precursors

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been granted a contract with Capra Biosciences, a Virginia-based biotech company focused on the cost-competitive production of petrochemical replacements using its modular bioreactor platform. ATCC is supporting a contract with Capra to work on the Defense Advanced Research Projects Agency’s

09/05/2025

RIVANNA awarded $2.21 million NIH grant to develop pediatric lumbar puncture ultrasound guidance system

RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) Direct to Phase II (R44) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop an ultrasound guidance solution for pediatric lumbar punctures (LPs) on its Accuro® 3S platform. Lumbar punctures